The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

NCI Director's Report

What NCI did with the money: Sharpless boosts funding for RPGs, centers, SPOREs, NCTN, and NCORP

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In addition to a $147 million increase to the Research Project Grant pool, NCI has added $60 million to targeted research opportunities and a $20 million increase for centers and SPOREs, and $10 million for the National Clinical Trials Network and the NCI Community Oncology Research Program.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.
By Claire Marie Porter
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account